Vitamin D deficiency in patients with active systemic lupus erythematosus
- 496 Downloads
We investigated the effects of disease activity on bone metabolism in 36 patients with systemic lupus erythematosus (SLE). Changes in bone remodeling were not explained by corticosteroid use. A high prevalence of 25OHD deficiency in SLE patients indicates the need for vitamin D replacement, mainly during high disease activity periods.
We investigated the effects of SLE disease activity on bone metabolism, their relation to inflammatory cytokines and vitamin D levels.
We performed a cross-sectional analysis of 36 SLE patients classified according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in high activity (group I: 12 patients, mean age 29.6 years) or in minimal activity (group II: 24 patients, mean age 30.0 years), and compared them to normal controls (group III: 26 women, 32.8 years). Serum calcium, phosphorus, parathyroid and sex hormones, bone remodeling markers, interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), IL-1, tumor necrosis factor-α (TNF), 25-hydroxivitamin D (25OHD), and 1,25-dihydroxyvitamin D3 were measured, plus bone mineral density.
All cytokines were significantly higher in SLE groups; IL-6 could differentiate SLE patients from controls. In group I, 25OHD levels were lower (P < 0.05), which was related to the SLEDAI (R = -0.65, P < 0.001). In multiple regression analysis, the 25OHD level was associated with SLEDAI, osteocalcin and bone-specific alkaline phosphatase. The SLEDAI score was positively correlated with all measured cytokines and especially TNF (R = 0.75, P < 0.001).
SLE patients demonstrated changes in bone remodeling strongly related to disease activity. A high prevalence of 25OHD deficiency was observed in SLE patients, indicating the need for vitamin D replacement.
KeywordsBone markers Bone metabolism Cytokines Osteoporosis Systemic lupus erythematosus Vitamin D
- 5.Kalla AA, Fataar AB, Jessop SJ, Bewerunge L (1993) Loss of trabecular bone mineral density in systemic lupus erythematosus. S Afr Med J 36:1726–1734Google Scholar
- 12.Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T et al (1997) Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24:303–308PubMedGoogle Scholar
- 14.Saraiva GL, Cendoroglo MS, Ramos LR, Araujo LMQ, Vieira JGH, Kunii I, Hayashi LF, Correa MP, Marise Lazaretti-Castro M (2005) Influence of ultraviolet radiation on the production of 25 hydroxyvitamin D in the elderly population in the city of Sa˜o Paulo (23 o 34’S), Brazil. Osteoporos Int 16:1649–1654PubMedCrossRefGoogle Scholar
- 18.Vieira JG, Nishida SK, Kasamatsu T (1994) Development and clinical application of an immunofluorometric assay for intact parathyroid hormone. Brazilian J Med Biol Res 27:2379–2382Google Scholar
- 22.Romas E, Martin TJ (1997) Cytokines in the pathogenesis of osteoporosis. Osteop Int 7(Suppl 3):S47–S53Google Scholar
- 29.Hearth-Holmes M, Elder C, Wolf RE (1993) Bone Mineral Density (BMD) in Patients with Systemic Lupus Erythematosus (SLE). Arthritis Rheum 36:S229Google Scholar
- 36.Holick MF (1995) Vitamin D: photobiology, metabolism, and clinical applications. In: DeGroot LJ, Besser M, Burger HG et al (eds) Endocrinology, 3rd edn. WB Saunders Company, Philadelphia, pp 990–1014Google Scholar
- 37.Bouillon R, Okamura WH, Norman AW (1995) Structure-function relationships in the vitamin D endocrine system. Endocr Rev 20:22–45Google Scholar